Metoclopramide and Tardive Dyskinesia

Metoclopramide (MCP) is a D-2 receptor blocker (Kebabian and Calne 1979), which has been available by prescription in the United States since 1979 for use as an antiemetic in a wide range of situations. One of the common indications for MCP is the e Woerner et al1993). There have been case reports but few systematic studies of MCP-associated TD (Sewell et al 1992; Sewell and Jeste 1992; Ganzini et a1 1993). We present hkre preliminary results of a clinical study of MCPassociated TD. We wished to study the frequency of dy&esia in patients with a history of exposure to MCP compared to a non MCP-treated comparison group. We also wished to study localization and course of MCP-associated TD, as well as factors such as the diagnosis of diabetes mellitus which might be associated with an increased risk of TD.